Evidence map›Paper›PMID 31190122›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2019

Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease.

S Geng, Z Kuang, P L Peissig, D Page, L Maursetter, K E Hansen

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07654231 (Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD), which is not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07654231 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Reducing Inflammation to Improve Vascular and Bone Outcomes With Low-dose Colchicine in CKD: A Pilot Randomized Open-Label Trial (RESOLVE-CKD Trial)

TypeinterventionalSponsorUniversity of Texas Southwestern Medical CenterRan2026 to 2027Enrolled60ConditionsChronic Kidney Disease Mineral and Bone Disorder, Hypertension, Diabetes, DyslipidemiaArmsLow-dose Colchicine at 0.5mg daily, Usual Care
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Parathyroid hormone and alkaline phosphatase are associated with fracture risk in non-dialysis-dependent chronic kidney disease.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Risk factors for hip and vertebral fractures in chronic kidney disease: the CRIC study.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2024
    Article
  15. Review
  16. Article
  17. Association between CKD-MBD and mortality in older patients with advanced CKD-results from the EQUAL study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Article
  18. Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

S GengDepartment of Computer Science, Princeton University, Princeton, NJ, USA.
Z KuangComputer Science Department, Stanford University, Stanford, CA, USA.
P L PeissigCenter for Computational and Biomedical Informatics, Marshfield Clinic Research Institute, Marshfield, WI, USA.
D PageDepartment of Biostatistics and Medical Informatics, Department of Computer Sciences, University of Wisconsin-Madison, Madison, WI, USA.
L MaursetterDepartment of Medicine, University of Wisconsin School of Medicine & Public Health, Mailbox 4124, Medical Foundation Centennial Building, 1685 Highland Avenue, Madison, WI, 53705-2281, USA.
K E HansenDepartment of Medicine, University of Wisconsin School of Medicine & Public Health, Mailbox 4124, Medical Foundation Centennial Building, 1685 Highland Avenue, Madison, WI, 53705-2281, USA. keh@medicine.wisc.edu.ORCID http://orcid.org/0000-0003-4338-6073
University of Wisconsin–Madison · USMarshfield Clinic · USPrinceton University · USStanford University · USUniversity of Wisconsin Foundation · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doctors do not know whether treatment of high parathyroid hormone levels is linked to better outcomes in their patients with kidney disease. In this study, lower parathyroid hormone levels at baseline were linked to lower risk of fracture, vascular events, and death in people with kidney disease. PURPOSE: Chronic kidney disease (CKD) affects ~ 20% of older adults, and secondary hyperparathyroidism (HPT) is a common condition in these patients. To what degree HPT predicts fractures, vascular events, and mortality in pre-dialysis CKD patients is debated. In stage 3 and 4 CKD patients, we assessed relationships between baseline serum PTH levels and subsequent 10-year probabilities of clinical fractures, vascular events, and death.

methodsWe used Marshfield Clinic Health System electronic health records to analyze data from adult CKD patients receiving care between 1985 and 2013, and whose PTH was measured using a second-generation assay. Covariates included PTH, age, gender, tobacco use, vascular disease, diabetes, hypertension, hyperlipidemia, obesity, GFR, and use of osteoporosis medications.

resultsFive thousand one hundred eight subjects had a mean age of 68 ± 17 years, 48% were men, and mean follow-up was 23 ± 10 years. Fractures, vascular events, and death occurred in 18%, 71%, and 56% of the cohort, respectively. In univariate and multivariate models, PTH was an independent predictor of fracture, vascular events, and death. The hazards of fracture, vascular events and death were minimized at a baseline PTH of 0, 69, and 58 pg/mL, respectively.

conclusionsWe found that among individuals with stage 3 and 4 CKD, PTH was an independent predictor of fractures, vascular events, and death. Additional epidemiologic studies are needed to confirm these findings. If a target PTH range can be confirmed, then randomized placebo-controlled trials will be needed to confirm that treating HPT reduces the risk of fracture, vascular events, and death.

Indexed as

AdultAgedAged, 80 and overBiomarkersComorbidityElectronic Health RecordsFemaleGlomerular Filtration RateHumansHyperparathyroidism, SecondaryKaplan-Meier EstimateMaleMiddle AgedOsteoporotic FracturesParathyroid HormoneRenal Insufficiency, ChronicBiomarkersParathyroid HormonePTH protein, humanChronic kidney diseaseFracturesMortalitySecondary hyperparathyroidismVascular events

Identifiers

PMID31190122
OpenAlexW2953202511

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.